Shares in Teva Pharmaceutical Industries (NYSE: TEVA) closed more than 5% higher on Wednesday. The Israeli drugmaker earlier ...

Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...

Teva Pharmaceutical Industries has reported positive outcomes from its multicentre Phase III SPACE trial of Ajovy ...

Teva (NYSE:TEVA) presented positive data from a Phase 3 study of its drug Ajovy in the prevention of episodic migraine in ...

Analyst evaluates Teva's stock performance and recommends holding due to revenue growth and successful debt reduction efforts ...

Teva Pharmaceutical shares have rebounded from lows, driven by debt reduction. Check out why I rate TEVA stock as Strong Buy.

AJOVY is already approved for the preventive treatment of migraine in adults who have at least 4 migraine days per month. TEVA closed Tuesday's trading at $17.53, up by 5.29 percent on the New ...

Teva (TEVA) presented data from its Phase 3 SPACE study evaluating the efficacy and safety of Ajovy for the prevention of episodic migraine in ...

The company is seeing continued market share growth of its two newest drugs, Austedo and Ajovy. Though Teva is seeing slower growth of Ajovy in the U.S. market, it expects sales to benefit from ...

SPACE is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety, and tolerability of subcutaneous administration of fremanezumab versus ...

Teva Pharmaceutical Industries has reported positive outcomes from its multicentre Phase III SPACE trial of Ajovy (fremanezumab) as a preventive treatment for episodic migraine in young ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...